{"resourceType": "Group", "meta": {"versionId": "5", "lastUpdated": "2025-03-15T21:15:32.464Z", "profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria"]}, "title": "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer", "status": "active", "url": "https://fevir.net/resources/Group/179619", "id": "179619", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "https://fevir.net/FOI", "value": "179619", "assigner": {"display": "Computable Publishing LLC"}}], "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Brian S. Alper"}}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as", "valueMarkdown": "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179619. Revised 2023-12-06. Available at: https://fevir.net/resources/Group/179619. Computable resource at: https://fevir.net/resources/Group/179619#json."}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "code": "active", "display": "Active"}]}}], "description": "**Study selection criteria**\nTypes of Studies.\nRandomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.\n\nTypes of participants.\nPatients aged \u226518 years with cytological or histological diagnosis of mHNPC.", "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "SystematicReviewEligibilityCriteria", "display": "SystematicReviewEligibilityCriteria"}]}}], "membership": "conceptual", "combinationMethod": "all-of", "characteristic": [{"description": "Randomized controlled clinical trials (RCTs)", "code": {"text": "Study Design"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/sevco", "code": "SEVCO:01003", "display": "randomized assignment"}]}, "exclude": false}, {"description": "parallel design", "code": {"text": "Study Design"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/sevco", "code": "SEVCO:01011", "display": "Parallel cohort design"}]}, "exclude": false}, {"description": "compared the association of ADT and chemotherapy (docetaxel), versus ADT alone", "code": {"text": "Comparison"}, "valueReference": {"type": "EvidenceVariable", "display": "GroupAssignment: ADT plus docetaxel vs. ADT alone"}, "exclude": false}, {"description": "Types of participants.\nPatients aged \u226518 years", "code": {"coding": [{"system": "http://snomed.info/sct", "code": "397669002", "display": "Age"}]}, "method": [{"text": "applied to participants in the studies"}], "valueQuantity": {"comparator": ">=", "value": 18, "unit": "years", "system": "http://unitsofmeasure.org", "code": "a"}, "exclude": false}, {"description": "Types of participants.\nPatients with cytological or histological diagnosis of mHNPC.", "code": {"coding": [{"system": "http://snomed.info/sct", "code": "64572001", "display": "Disease (disorder)"}]}, "method": [{"text": "applied to participants in the studies"}, {"text": "cytological or histological diagnosis"}], "valueCodeableConcept": {"text": "metastatic hormone-naive prostate cancer"}, "exclude": false}], "name": "SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer", "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}}